Skip to content

Genmab

US · GMAB #860 by market cap Listed 2019
50.60 -0.75 -1.46%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:56

Recent news

  • Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Cuts Target Price to $56
    \u5e02\u573a\u8d44\u8baf · 2026/11/13
  • Rating change
    H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $70
    \u5e02\u573a\u8d44\u8baf · 2026/10/29
  • Rating change
    H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $50
    \u5e02\u573a\u8d44\u8baf · 2026/10/7
  • Rating change
    H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
    \u5e02\u573a\u8d44\u8baf · 2026/10/26
  • Rating change
    Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Raises Target Price to $42
    \u5e02\u573a\u8d44\u8baf · 2026/10/20
  • Rating change
    Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Raises Target Price to $57
    \u5e02\u573a\u8d44\u8baf · 2026/10/31
  • Rating change
    H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $70
    \u5e02\u573a\u8d44\u8baf · 2026/10/31
  • A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $57 to $70
    \u5e02\u573a\u8d44\u8baf · 2026/11/7
  • Rating change
    TD Cowen Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $43
    \u5e02\u573a\u8d44\u8baf · 2026/10/6
  • Rating change
    Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $58
    \u5e02\u573a\u8d44\u8baf · 2026/10/7
  • Rating change
    Truist Financial Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $45
    \u5e02\u573a\u8d44\u8baf · 2026/10/9
  • Rating change
    BofA Securities Maintains Genmab(GMAB.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/11/3
  • Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $65
    \u5e02\u573a\u8d44\u8baf · 2026/10/29
  • Rating change
    TD Cowen Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $52
    \u5e02\u573a\u8d44\u8baf · 2026/10/26
  • Rating change
    Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/10/5
  • Rating change
    William Blair Maintains Genmab(GMAB.US) With Buy Rating
    \u5e02\u573a\u8d44\u8baf · 2026/10/5
  • US Stock Market Alert | Genmab (GMAB.US) Surges Nearly 26% Intraday, Hitting an All-Time High
    Zhitong Finance · 2026/10/28
  • Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $60
    \u5e02\u573a\u8d44\u8baf · 2026/10/28
  • Rating change
    Guggenheim Maintains Genmab(GMAB.US) With Buy Rating, Raises Target Price to $54
    \u5e02\u573a\u8d44\u8baf · 2026/10/5
  • Rating change
    A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $65 to $80
    \u5e02\u573a\u8d44\u8baf · 2026/10/30
  • Rating change
    H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $40
    \u5e02\u573a\u8d44\u8baf · 2026/9/14
  • Rating change
    A Quick Look at Today's Ratings for Genmab(GMAB.US), With a Forecast Between $40 to $40
    \u5e02\u573a\u8d44\u8baf · 2026/6/30
  • H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
    \u5e02\u573a\u8d44\u8baf · 2026/10/19
  • Rating change
    Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $33
    \u5e02\u573a\u8d44\u8baf · 2026/7/23
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Genmab (GMAB) and Hinge Health, Inc. Class A (HNGE)
    TipRanks · 2026/6/30

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:56:12 · For reference only, not investment advice and not tailored to your situation.

Genmab discussion 0 comments

Add a comment